Myomo (NYSEAMERICAN:MYO) Insider Sells $29,842.50 in Stock

Posted by Geri Gentry on Aug 24th, 2026

Myomo, Inc. (NYSEAMERICAN:MYO – Get Free Report) insider Harry Kovelman sold 17,250 shares of Myomo stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $1.73, for a total transaction of $29,842.50. Following the completion of the transaction, the insider directly owned 105,983 shares in the company, valued at approximately $183,350.59. The trade was a 14.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Harry Kovelman also recently made the following trade(s):

On Wednesday, May 27th, Harry Kovelman sold 20,464 shares of Myomo stock. The shares were sold at an average price of $1.00, for a total transaction of $20,464.00.
On Thursday, May 28th, Harry Kovelman sold 11,536 shares of Myomo stock. The stock was sold at an average price of $1.02, for a total transaction of $11,766.72.

Myomo Stock Performance

Shares of NYSEAMERICAN:MYO opened at $1.73 on Monday. Myomo, Inc. has a 12 month low of $0.60 and a 12 month high of $1.89. The company has a quick ratio of 2.01, a current ratio of 2.31 and a debt-to-equity ratio of 1.98. The company’s fifty day simple moving average is $1.22 and its 200 day simple moving average is $0.98. The firm has a market cap of $68.53 million, a price-to-earnings ratio of -5.09 and a beta of 1.50.

Myomo (NYSEAMERICAN:MYO – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. The business had revenue of $11.70 million for the quarter, compared to analysts’ expectations of $10.35 million. Myomo had a negative net margin of 33.53% and a negative return on equity of 138.85%. As a group, research analysts forecast that Myomo, Inc. will post -0.33 EPS for the current fiscal year.

Institutional Trading of Myomo

Hedge funds and other institutional investors have recently made changes to their positions in the business. XTX Topco Ltd bought a new stake in shares of Myomo in the fourth quarter worth $148,000. AQR Capital Management LLC grew its position in Myomo by 47.8% in the fourth quarter. AQR Capital Management LLC now owns 434,376 shares of the company’s stock valued at $395,000 after purchasing an additional 140,427 shares in the last quarter. State Street Corp grew its position in Myomo by 5.1% in the fourth quarter. State Street Corp now owns 399,853 shares of the company’s stock valued at $364,000 after purchasing an additional 19,563 shares in the last quarter. Wells Fargo & Company MN increased its stake in Myomo by 103.1% in the 4th quarter. Wells Fargo & Company MN now owns 38,707 shares of the company’s stock valued at $35,000 after buying an additional 19,646 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in Myomo in the 4th quarter valued at $64,000. 44.99% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets upped their price objective on Myomo from $9.50 to $10.00 and gave the stock a “buy” rating in a research report on Monday, June 8th. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $10.00.

Check Out Our Latest Stock Analysis on MYO

Myomo Company Profile

(Get Free Report)

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.